Compare TSLX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | NRIX |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2011 | 2020 |
| Metric | TSLX | NRIX |
|---|---|---|
| Price | $18.21 | $16.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $21.72 | ★ $30.58 |
| AVG Volume (30 Days) | 899.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | ★ 11.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.92 | $26.32 |
| P/E Ratio | $10.25 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $16.99 | $8.18 |
| 52 Week High | $25.17 | $22.50 |
| Indicator | TSLX | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 55.45 |
| Support Level | $17.25 | $14.61 |
| Resistance Level | $18.57 | $16.47 |
| Average True Range (ATR) | 0.49 | 0.92 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 58.14 | 68.29 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.